Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4399 SANTA ANITA AVE EL MONTE CA 91731 |
Tel: | 1-415-2174964 |
Website: | https://www.fulgentgenetics.com |
IR: | See website |
Key People | ||
Ming Hsieh Chairman of the Board, Chief Executive Officer | Jian Xie President, Chief Operating Officer | Paul Kim Chief Financial Officer | Hanlin Gao Chief Scientific Officer, Laboratory Director |
Business Overview |
Fulgent Genetics, Inc. is a technology-based company with a clinical diagnostic business and a therapeutic development business. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its business is built on its technology platform, which includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The Company's technology platform offers a test menu. The Company also offers next-generation sequencing (NGS) services. |
Financial Overview |
For the nine months ended 30 September 2023, Fulgent Genetics Inc revenues decreased 60% to $218.7M. Net loss totaled $39.7M vs. income of $167.2M. Revenues reflect Institutional segment decrease of 67% to $103.8M, Insurance segment decrease of 52% to $112.7M, United States segment decrease of 62% to $204.1M. Net loss reflects Research and development increase of 40% to $18.6M (expense). |
Employees: | 1,012 as of Feb 15, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $353.80M as of Sep 30, 2023 |
Annual revenue (TTM): | $286.41M as of Sep 30, 2023 |
EBITDA (TTM): | -$51.57M as of Sep 30, 2023 |
Net annual income (TTM): | -$63.51M as of Sep 30, 2023 |
Free cash flow (TTM): | $21.45M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 29,633,057 as of Nov 1, 2023 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |